<SEC-DOCUMENT>0001326110-25-000129.txt : 20251020
<SEC-HEADER>0001326110-25-000129.hdr.sgml : 20251020
<ACCEPTANCE-DATETIME>20251020161627
ACCESSION NUMBER:		0001326110-25-000129
CONFORMED SUBMISSION TYPE:	DEF 14C
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251020
FILED AS OF DATE:		20251020
DATE AS OF CHANGE:		20251020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14C
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		251403995

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(844) 696-5235

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14C
<SEQUENCE>1
<FILENAME>ibrx-20251020xdef14c.htm
<DESCRIPTION>DEF 14C
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i015f2113371141e185483cd2f079d7d6_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><img alt="black-linea.jpg" src="black-linea.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SCHEDULE&#160;14C INFORMATION</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Statement Pursuant to Section 14(c) of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><img alt="black-linea.jpg" src="black-linea.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div style="margin-top:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the Appropriate Box&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  Preliminary Information Statement</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;  Definitive Information Statement</font></div></td></tr></table></div><div style="margin-top:18pt;text-align:center"><img alt="immunitybio-logox2024xcoloa.jpg" src="immunitybio-logox2024xcoloa.jpg" style="height:110px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"></div><div style="margin-top:15pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%">ImmunityBio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name of Registrant as Specified in its Charter)</font></div><div style="margin-top:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of Filing Fee (Check all Boxes that Apply)&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;  No fee required.</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  Fee paid previously with preliminary materials.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  Fee computed on table in exhibit required by Item&#160;25(b) of Schedule 14A (17 CFR 240.14a-101) per Item&#160;1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11.</font></div></td></tr></table></div><div style="margin-top:93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><img alt="immunitybio-logox2024xcoloa.jpg" src="immunitybio-logox2024xcoloa.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTICE OF ACTION BY WRITTEN CONSENT OF OUR STOCKHOLDERS AND INFORMATION STATEMENT</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Mailing&#58; On or about October&#160;20, 2025</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To Our Stockholders&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This notice and the accompanying information statement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is furnished by the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of ImmunityBio,&#160;Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">we</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">us</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Company, a Delaware corporation, is a public company registered with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Information Statement has been filed with the SEC and is being furnished, pursuant to Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to notify the holders of record of our common stock, par value $0.0001&#160;per share (our &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as of the close of business on October&#160;7,&#160;2025 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Record Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of actions we are taking pursuant to a written consent representing a majority of the voting power of our Common Stock, in lieu of a meeting of stockholders.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Information Statement is to inform the Company&#8217;s stockholders of the action taken by our Board on October&#160;6,&#160;2025 and by the holders of a majority of the issued and outstanding shares of our Common Stock by written consent delivered to the Company on October&#160;7,&#160;2025 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Written Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), resolving to amend the Company&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restated Certificate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the form attached to the Information Statement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate of Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). This consent was sufficient to approve the Certificate of Amendment under Delaware law and the Restated Certificate. The attached Information Statement describes the Certificate of Amendment approved by Stockholder Written Consent, which will increase the Company&#8217;s authorized shares of Common Stock to 1,650,000,000&#160;shares from 1,350,000,000&#160;shares. The change in authorized capital will become effective no earlier than twenty&#160;(20)&#160;calendar days after the filing and dissemination of the Information Statement.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO VOTE OR OTHER ACTION OF THE COMPANY&#8217;S STOCKHOLDERS IS REQUIRED IN CONNECTION WITH THE INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no stockholder dissenters&#8217; or appraisal rights in connection with any of the matters discussed in the accompanying Information Statement. Please read this Information Statement carefully and entirely. It describes the terms of the actions taken by the stockholders. Although you will not have an opportunity to vote on the approval of the Certificate of Amendment, the Information Statement contains important information about the Certificate of Amendment.</font></div><div style="margin-top:9pt;padding-left:324pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.714%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By Order of the Board of Directors,</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:62pt"><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div><img alt="richsignaturea.jpg" src="richsignaturea.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:135px"></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;20, 2025</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">ImmunityBio, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3530 John Hopkins Court San Diego, CA 92121</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Office&#58; +1-844-696-5235   Email&#58; info&#64;ImmunityBio.com</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTIONS, OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURES IN THE INFORMATION STATEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Information Statement is dated October&#160;20, 2025 and is first being mailed to our stockholders on or about October&#160;20, 2025. The Information Statement can also be accessed on our proxy hosting website at </font><font style="color:#ff7950;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">https&#58;&#47;&#47;materials.proxyvote.com&#47;45256X</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_10"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="immunitybio-logox2024xcoloa.jpg" src="immunitybio-logox2024xcoloa.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INFORMATION<font id="ia970d09f90944c33879b747c2dc1283a_3459"></font> STATEMENT</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGARDING CORPORATE ACTION TAKEN BY WRITTEN CONSENT IN LIEU OF SPECIAL MEETING.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO VOTE OR OTHER CONSENT OF OUR STOCKHOLDERS IS SOLICITED IN CONNECTION WITH THIS INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information statement (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is being furnished by the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of ImmunityBio,&#160;Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">we</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">us</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">our</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on or about October&#160;20, 2025, to the holders of record at the close of business on October&#160;7,&#160;2025 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Record Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the outstanding shares of the Company&#8217;s common stock, par value $0.0001&#160;per share (our &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The purpose of this Information Statement is to inform ImmunityBio&#8217;s stockholders of an action by written consent of holders of a majority of the Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Written Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). This Information Statement can also be accessed on our proxy hosting website at </font><font style="color:#ff7950;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">https&#58;&#47;&#47;materials.proxyvote.com&#47;45256X</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions contemplated by the Stockholder Written Consent are being taken without notice, meetings or votes in accordance with the Delaware General Corporation Law (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DGCL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company&#8217;s Amended and Restated Certificate of Incorporation (the&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restated Certificate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and its Bylaws. This Information Statement is being mailed to the stockholders of the Company as of the Record Date, October&#160;7,&#160;2025.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;6,&#160;2025, the Board approved, and recommended to stockholders for approval, an amendment to the Restated Certificate that will increase the Company&#8217;s authorized shares of Common Stock to 1,650,000,000&#160;shares from 1,350,000,000&#160;shares (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate of Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The full text of the Certificate of Amendment is attached to this Information Statement as </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i015f2113371141e185483cd2f079d7d6_40" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7,&#160;2025, holders of 649,794,019&#160;shares of Common Stock, representing approximately 66.0%, of our Common Stock voting power (and thus a majority of voting power), executed and delivered to the Company the Stockholder Written Consent to approve the Certificate of Amendment. The Stockholder Written Consent was sufficient to approve the Certificate of Amendment under the DGCL and our Restated Certificate.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any substantial interest, direct or indirect, by security holders or otherwise, that is in opposition to matters of action being taken. In addition, pursuant to the DGCL, this action to be taken by majority written consent in lieu of a special stockholder meeting does not create appraisal or dissenters&#8217; rights.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has determined to pursue stockholder action by majority written consent of those shares entitled to vote as of the Record Date, to reduce the costs and management time required to hold a special meeting of stockholders, and to implement the above action in a timely manner.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;14(c) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), actions taken by written consent without a meeting of stockholders cannot become effective until twenty&#160;(20)&#160;calendar days after the mailing date of this Information Statement, or as soon thereafter as is practicable. We are not seeking written consent from any stockholders other than as set forth above, and our other stockholders will not be given an opportunity to vote with respect to the actions taken. All necessary corporate approvals have been obtained, and this Information Statement is furnished solely for the purpose of advising stockholders of the actions taken by written consent and giving stockholders advance notice of the actions taken.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  1  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_13"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Information Statement and other reports that we file with the SEC may contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Exchange Act, which are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statement of the plans and objectives of management for future operations, the need and ability to obtain additional financing to fund our operations and complete the development and commercialization of our various product and product candidates and the timing thereof, the terms of any such financing, the period of time for which we expect the additional shares authorized under the Certificate of Amendment to cover all the Company&#8217;s current, committed issuances of Common Stock and the Company&#8217;s expected funding needs, and any statement of assumptions underlying any of the foregoing. These statements may contain words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;projects,&#8221; and words of similar meaning. These statements relate to our future business and financial performance.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual outcomes may differ materially from these statements. The risks listed in this Information Statement, as well as any cautionary language in this Information Statement, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from any expectations we describe in our forward-looking statements. There may be other risks that we have not described that may adversely affect our business and financial condition. Except as required by law, we disclaim any obligation to update or revise any of the forward-looking statements contained in this Information Statement. We caution you not to rely upon any forward-looking statement as representing our views as of any date after the date of this Information Statement. You should carefully review the information and risk factors set forth in other reports and documents that we file from time to time with the SEC.</font></div><div id="i015f2113371141e185483cd2f079d7d6_16"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">OUTSTANDING VOTING SECURITIES AND CONSENTING STOCKHOLDERS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Record Date, ImmunityBio had 984,965,179&#160;issued and outstanding shares of Common Stock (excluding 163,800&#160;shares held by a majority-owned subsidiary of the Company that are treated as treasury shares for accounting purposes). Each share of Common Stock entitles the holder thereof to one&#160;vote on all matters submitted to stockholders.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7,&#160;2025, holders of 649,794,019&#160;shares of Common Stock executed and delivered to the Board the Stockholder Written Consent, representing approximately 66.0% of our Common Stock voting power (and thus a majority of voting power), approving the Certificate of Amendment to increase the amount of authorized Common Stock. Because the action was approved by stockholders owning a majority of our outstanding voting power, no proxies are being solicited with this Information Statement. No consideration was paid for the Stockholder Written Consent.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;228 of the DGCL provides in substance that unless a company&#8217;s certificate of incorporation provides otherwise, stockholders may take any action without a meeting of stockholders, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is signed by stockholders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize and take such action at a meeting at which all shares entitled to vote thereon were present and voted.</font></div><div id="i015f2113371141e185483cd2f079d7d6_19"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NO APPRAISAL RIGHTS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware corporate law, stockholders have no appraisal or dissenters&#8217; rights in connection with the Certificate of Amendment.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  2  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_22"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INTERESTS OF CERTAIN PARTIES IN THE MATTERS TO BE ACTED UPON</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the directors or executive officers of the Company have any substantial interest resulting from the Certificate of Amendment that is not shared by all other stockholders, pro rata, and in accordance with their respective interests.</font></div><div id="i015f2113371141e185483cd2f079d7d6_25"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COST OF THIS INFORMATION STATEMENT</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entire cost of furnishing this Information Statement will be borne by the Company. We will request brokerage houses, nominees, custodians, fiduciaries, and other like parties to forward this Information Statement to the beneficial owners of our Common Stock held of record, as of the Record Date, by them.</font></div><div id="i015f2113371141e185483cd2f079d7d6_28"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">HOUSEHOLDING OF STOCKHOLDER MATERIALS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial owners of common stock who share a single address will receive only one&#160;copy of this Information Statement. This practice, known as &#8220;householding,&#8221; is designed to reduce printing and mailing costs. If any beneficial stockholder(s) sharing a single address wish to discontinue householding and receive a separate copy of this Information Statement, we will have a separate copy promptly delivered to them upon their written or oral request. To make the request, they may contact Broadridge&#160;Investor Communications (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broadridge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), either by calling 866-540-7095, or by writing to Broadridge, Householding Department, 51&#160;Mercedes Way, Edgewood, NY&#160;11717, and including their name, the name of their broker, or other nominee, and their account number(s). Beneficial owners may also contact Broadridge if they received multiple copies of the Information Statement and prefer to receive a single copy in the future.</font></div><div id="i015f2113371141e185483cd2f079d7d6_31"></div><div style="margin-top:18pt;text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED SHARES OF COMMON STOCK</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Restated Certificate currently authorizes 1,350,000,000&#160;shares of Common Stock and 20,000,000&#160;shares of preferred stock, par value $0.0001&#160;per share.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7,&#160;2025, the consenting stockholders approved the filing of the Certificate of Amendment to increase the authorized shares of Common Stock to 1,650,000,000&#160;shares from 1,350,000,000&#160;shares. The Certificate of Amendment was previously approved by the Board.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reasons for the Increase in Authorized Shares of Common Stock</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;7,&#160;2025, there were 984,965,179&#160;shares of Common Stock issued and outstanding. In order to provide future funding for the Company&#8217;s operations, it will be necessary to raise additional capital. One of the most effective ways for us to raise capital is to issue additional shares of Common Stock, or other instruments that are convertible into Common Stock. Most lenders that fund convertible instruments require that the borrower direct its stock transfer agent to establish a reserve of authorized shares to be available for shares that the Company has committed to, or may have to, issue, including derivative securities and certain existing contingent obligations requiring the issuance of shares of Common Stock. In the event that there are insufficient authorized shares to honor the issuance of any shares to which the Company has already committed, there may be contractual penalties. The increase in the Company&#8217;s authorized shares to 1,650,000,000&#160;shares from 1,350,000,000&#160;shares is intended to provide adequate authorized shares to cover all the Company&#8217;s current, committed issuances of Common Stock and the Company&#8217;s expected funding needs for at least the next 12&#160;months.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  3  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Effects of the Increase in Authorized Shares of Common Stock</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the authorization of additional shares of Common Stock is intended to increase our financial flexibility, the sale and issuance of such additional shares will result in the dilution of our existing stockholders. Upon the occurrence of the sale and issuance of all additional 300,000,000&#160;shares authorized by the Certificate of Amendment, our existing stockholders would be diluted substantially. If we choose to raise capital by incurring debt through an instrument convertible into Common Stock, the number of shares of Common Stock issuable upon such conversion would likely be contingent on a number of factors currently unknown to us, such as the market price of our Common Stock and certain interest rates. Any dilution of our Common Stock resulting from this Certificate of Amendment, whether immediate or over time, could cause the price per share of our Common Stock to decline significantly, which could result in financial harm to our existing stockholders.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Date</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Rule 14c-2 of the Exchange Act, the Certificate of Amendment shall be effective no earlier than twenty (20)&#160;calendar days after this Information Statement is first mailed to stockholders of the Company. We anticipate the effective date to be on or about November&#160;10, 2025.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  4  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_34"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS </font></div><div style="text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AND MANAGEMENT</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information, as of October&#160;7,&#160;2025, with respect to the holdings of (i)&#160;each person who is the beneficial owner of more than 5%&#160;of our Common Stock, (ii)&#160;each of our directors, (iii)&#160;each executive officer, and (iv)&#160;all our current directors and executive officers as a group. Beneficial ownership representing less than&#160;1% is denoted with an asterisk&#160;(*) in the table below.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership of our Common Stock is determined in accordance with the rules of the SEC and includes any shares of Common Stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60&#160;days of October&#160;7,&#160;2025.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, we believe that the persons named in this table have sole voting and investment power with respect to all shares of Common Stock held by them. Applicable percentage ownership in the following table is based on 984,965,179&#160;shares of Common Stock outstanding as of October&#160;7,&#160;2025 plus, for each individual, any securities that individual has the right to acquire within 60&#160;days of that date.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Address of Beneficial Owner (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br>Shares of <br>Common <br>Stock <br>Beneficially <br>Owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage <br>of <br>Common <br>Stock <br>Beneficially <br>Owned</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">5% Stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patrick Soon-Shiong, M.D., FRCS (C), FACS (2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743,971,200</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.94&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital, LLC (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,465,529</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.49&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cambridge Equities, LP (4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,705,814</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Capital Equity, LLC (5)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,511,412</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantWorks, LLC (6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,535,253</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other Directors and Named Executive Officers&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Adcock (7)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314,905</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Sachs (8)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,083</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael D. Blaszyk (9)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795,479</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wesley Clark (10)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,770</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheryl L. Cohen (11)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,514</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Maxwell, M.D., M.B.A., FRCSC (12)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,770</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christobel Selecky (12)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,770</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry J. Simon, M.D. (13)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507,333</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">All directors and executive officers as a group (9 persons) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(14)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,299,824</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.48&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________________</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">The address of each of the individuals named in the table above is c&#47;o ImmunityBio,&#160;Inc., 3530&#160;John Hopkins Court, San&#160;Diego, California&#160;92121. The address of each of the entities named in the table above is 450&#160;Duley Road, El Segundo, California 90245.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of&#160;(i)&#160;261,705,814&#160;shares held by Cambridge Equities, LP (Cambridge)&#59; (ii)&#160;246,412,277&#160;shares held by Nant&#160;Capital,&#160;LLC (Nant&#160;Capital)&#59; (iii)&#160;47,557,934&#160;shares held by NantMobile,&#160;LLC (NantMobile)&#59; (iv)&#160;32,606,985&#160;shares held by NantCancerStemCell,&#160;LLC (NCSC)&#59; (v)&#160;29,546,190&#160;shares held directly by Dr.&#160;Soon-Shiong&#59; (vi)&#160;9,986,920&#160;shares held by NantWorks, LLC (NantWorks)&#59; (vii)&#160;8,383,414&#160;shares held by NantBio,&#160;Inc. (NantBio)&#59; (viii)&#160;7,976,159&#160;shares held by California Capital Equity,&#160;LLC (California&#160;Capital)&#59; (ix)&#160;5,618,326&#160;shares held by the Chan Soon-Shiong Family Foundation&#59; (x)&#160;93,053,252&#160;shares that Nant&#160;Capital has the right to acquire within 60&#160;days of October&#160;7,&#160;2025 pursuant to the conversion of a promissory note&#59; and (xi)&#160;1,123,929&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  5  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;246,412,277&#160;shares held by Nant&#160;Capital and (ii)&#160;93,053,252&#160;shares that Nant&#160;Capital has the right to acquire with 60&#160;days of October&#160;7,&#160;2025 pursuant to the conversion of a promissory note. Dr.&#160;Soon-Shiong is the sole member of Nant&#160;Capital and thus may be deemed to have beneficial ownership of and voting and dispositive power over the shares held by Nant&#160;Capital.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of 261,705,814&#160;shares held by Cambridge. MP&#160;13 Ventures, LLC (MP&#160;13 Ventures) is the general partner of Cambridge and thus may be deemed to have beneficial ownership of the shares held by Cambridge. Dr.&#160;Soon-Shiong, Executive Chairman of the Board and Global Chief Scientific and Medical Officer of the Company, is the sole member of MP&#160;13 Ventures and has voting and dispositive power over the shares held by Cambridge. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;7,976,159&#160;shares held by California&#160;Capital&#59; (ii)&#160;47,557,934&#160;shares held by NantMobile&#59; (iii)&#160;32,606,985&#160;shares held by NCSC&#59; (iv)&#160;9,986,920&#160;shares held by NantWorks&#59; and (v)&#160;8,383,414&#160;shares held by NantBio. Dr.&#160;Soon-Shiong owns all the equity interests in California&#160;Capital and has voting and dispositive power over the shares held by California&#160;Capital.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;9,986,920&#160;shares held by NantWorks&#59; (ii)&#160;8,383,414&#160;shares held by NantBio&#59; (iii)&#160;47,557,934&#160;shares held by NantMobile&#59; and (iv)&#160;32,606,985&#160;shares held by NCSC. NantWorks is the majority stockholder of NantBio, NantMobile, and NCSC and thus may be deemed to control NantBio, NantMobile, and NCSC. NantBio is the sole shareholder of NCSC. Dr.&#160;Soon-Shiong indirectly beneficially owns equity interests in NantWorks and thus may be deemed to control NantWorks and each entity directly or indirectly controlled by NantWorks (including NantBio, NantMobile, and NCSC and has voting and dispositive power over the shares held by NantWorks. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;334,418&#160;shares held directly by Mr.&#160;Adcock and (ii)&#160;1,980,487&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;225,620&#160;shares held directly by Mr.&#160;Sachs and (ii)&#160;391,463&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Consists of (i)&#160;193,667&#160;shares held directly by Mr.&#160;Blaszyk&#59; (ii)&#160;71,915&#160;shares held indirectly&#59; and (iii)&#160;529,897&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.8pt">Consists of (i)&#160;8,000&#160;shares held directly by Gen.&#160;Clark and (ii)&#160;451,770&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.8pt">Consists of (i)&#160;200,617&#160;shares held directly by Ms.&#160;Cohen and (ii)&#160;529,897&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.8pt">Consists of 451,770&#160;shares issuable upon the exercise of stock options that were exercisable by Dr.&#160;Maxwell and Ms.&#160;Selecky as of October&#160;7,&#160;2025.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.8pt">Consists of (i)&#160;3,243,571&#160;shares held directly by Dr.&#160;Simon and (ii)&#160;263,762&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.8pt">Consists of (i)&#160;33,752,083&#160;shares held directly&#59; (ii)&#160;620,319,744&#160;shares held indirectly&#59; (iii)&#160;93,053,252&#160;shares that Nant&#160;Capital has the right to acquire within 60&#160;days of October&#160;7,&#160;2025 pursuant to the conversion of a promissory note&#59; and (iv)&#160;6,174,745&#160;shares issuable upon the exercise of stock options that were exercisable as of October&#160;7,&#160;2025.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  6  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_37"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ADDITIONAL INFORMATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Information Statement should be read in conjunction with certain reports that we previously filed with the SEC, including&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2024 and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Quarterly Reports on Form&#160;10-Q for the three-month periods ended March&#160;31,&#160;2025 and June&#160;30,&#160;2025.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about our Company is available on our website at </font><font style="color:#8ab6cc;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ir.immunitybio.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available on our website, free of charge, copies of our Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it, to the SEC. All reports we file with the SEC are available free of charge via EDGAR through the SEC website at www.sec.gov. We have included the web addresses of ImmunityBio and the SEC as inactive textual references only. Except as specifically incorporated by reference into this Information Statement, information on these websites is not part of this filing.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a matter of regulatory compliance, we are sending you this Information Statement that describes the purpose and effect of the above action. Your consent to the above action is not required and is not being solicited in connection with this action. This Information Statement is intended to provide our stockholders with information required by the rules and regulations of the Exchange Act.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ImmunityBio, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#124;  7  &#124;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information Statement</font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_40"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1b4486;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Pursuant to Section&#160;242 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Corporation Law of the State of Delaware)</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), hereby certifies as follows&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The name of this corporation is ImmunityBio,&#160;Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March&#160;12,&#160;2014 under the name Conkwest, Inc., and the Corporation&#8217;s Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on July&#160;31,&#160;2015, as amended on March&#160;9,&#160;2021, February&#160;1,&#160;2022, and October&#160;18,&#160;2023 (as amended, the &#8220;Amended and Restated Certificate of Incorporation&#8221;).</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The Board of Directors of the Corporation duly adopted resolutions proposing to amend the Amended and Restated Certificate of Incorporation, declaring such amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The amendment to the Amended and Restated Certificate of Incorporation set forth in paragraph&#160;5 of this Certificate of Amendment was duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The amendment to the Amended and Restated Certificate of Incorporation set forth in paragraph&#160;5 of this Certificate of Amendment was duly approved by the stockholders of the Corporation in accordance with the provisions of Sections&#160;228 and 242 of the General Corporation Law of the State of Delaware.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Article&#160;IV, Section&#160;1 of the Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-top:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This Corporation is authorized to issue two&#160;classes of stock, to be designated, respectively, as Common Stock and Preferred Stock. The total number of shares of stock that the Corporation shall have authority to issue is 1,670,000,000&#160;shares, of which 1,650,000,000&#160;shares are Common Stock, $0.0001&#160;par value per share, and 20,000,000&#160;shares are Preferred Stock, $0.0001&#160;par value per share.&#8221;</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i015f2113371141e185483cd2f079d7d6_43"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by a duly authorized officer of the Corporation on this 10th day of November&#160;2025.</font></div><div style="margin-top:12pt;padding-left:324pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.714%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IMMUNITYBIO, INC.</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:62pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>black-linea.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 black-linea.jpg
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M ?_$ $L  0$                    + 0$                     $ $
M                    $0$                     _]H # ,!  (1 Q$
3/P"?^                 #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>immunitybio-logox2024xcoloa.jpg
<DESCRIPTION>IMMUNITYBIO LOGO
<TEXT>
begin 644 immunitybio-logox2024xcoloa.jpg
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M .,  0 " P$!  ,!           )"@<("P8% 0($ P$!  ,! 0$! 0$
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*.3N2<M%^-FGTX"G2
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M*/I*/H'.6)8GP2NAD^48XM/2#0K;(WMD8V1G@N (Z#I7TA,4O3Q" =1 H=1
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MH_6%D<HW5X8F&YEO7QO<0"7,;%$0PD^U!<X[NJI*P+BI=7 QZ& /<(66S7-
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M;MFZ!"I(H((I%*FBBBF4"E*4 *4H  !TSE5SG.<7.)+B:DG63RE;< &@-:*
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MW*1QB$4V[6.!'R5G+O*.+W$/%1BT^3\$)LL(MG%LG5]XZ9[N^?4MH6QU<1N
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MN8<1\_)/Q/\ O!=(=\P8RC55C),FDBR7 H+LWS9%VU6 ARJ%!5NX(HDH!3E
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M<%KIY4*?B</O!Z%^ROKKZR=R9V9Z/OF1-^)2^2@7/?%3SCC^J,^'(KCG;_\
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M=NI[2S+V==;OJIQPL=ZD4%$#[.OCY[$^-,Q/:*]5FB, U=%,;H)RJ3A)(H=
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M\O()(.56QR>[T%@6]K;5'B!QGP? (),.RW)'>8Z06[S:.AA/NG.&B1XV,:2
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M74KNDM>US=YM31U*BI%:$@PV,9?PC'F,9BD(DZLU::N:176-YI!H=HK30#K
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M$TR@4H   &5>662>5TTSB^9[BYSB:DDFI))TDDZ23K*FF,9&P1Q@-C:  !H
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J_H?@_L9Q@=:Z'7[Y_$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>richsignaturea.jpg
<DESCRIPTION>SIGNATURE
<TEXT>
begin 644 richsignaturea.jpg
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M,C/_Q  8 0$! 0$!                 P(!!/_$ #,1  (! @,%!P,$ @,
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M$6)$BL(;8C1HS#:&6&&4(:9:0AMM"4)QC B5;O,::YW&]UO4GN_$1F?K710
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MPEA%E*%4"U?IP5/NFJUM:.G?[EM>LUBMTJO!:E3J^$JE5K@V(&KU:K8J"#
MA$!E,>"+#AQC$8>-'PV$(9BPX<=F.PTE+;3:4XQC@B<YP!P!P!P!P"FOZ/-2
MO:GV#U!YJ424ZKK+TN46O7:J[@_L2\X?;<%-; !0C+:'%12 IMX!IROX;_\
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M#Z=/H-T@Z$[Y[0:XVKV:8V'IX)6"U5D7B\:[- #)\Y>ZO41@HN,!ZKJ<W_\
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MJT[&Z\]B*7K. >G "?7O6NNKIK;6("1$E*9P(W#>;4R$C6,NQE#&9K>RK3&
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M5+N=+K=HDC%(<_*A0]\X-G.PLI=_[$YC+;RES_?'PK^^!5K)F0N . . . .
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M<&E8GWN8AF0TS$D09A8<=Q#*P9D;#KF&OO4,---IV:LS,?!P< < < < < <
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-P!P!P!P!P!P!P#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
